Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study

Blood

Volumn 99, Issue 10, 2002, Pages 3530-3539

  Sawyers, Charles L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Hochhaus, Andreas ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Feldman, Eric ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Goldman, John M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Miller, Carole B ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Ottmann, Oliver G ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Schiffer, Charles A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Talpaz, Moshe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Guilhot, Francois ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Deininger, Michael W N ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Fischer, Thomas ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   O'Brien, Steve G ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Stone, Richard M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Gambacorti Passerini, Carlo B ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Russell, Nigel H ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Reiffers, Jose J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Shea, Thomas C ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Chapuis, Bernard ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Coutre, Steven ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Tura, Sante ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Morra, Enrica ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Larson, Richard A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Saven, Alan ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Peschel, Christian ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Gratwohl, Alois ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Mandelli, Franco ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Ben Am, Monique ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Gathmann, Insa ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Capdeville, Renaud ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Paquette, Ronald L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   Druker, Brian J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,aa,ab,ac}   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f GOETHE UNIVERSITY   (Germany)

^g WAYNE STATE UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY OF LEIPZIG   (Germany)

^k UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ SAN GERARDO HOSPITAL   (Italy)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^q UNIVERSITÉ DE BORDEAUX   (France)

^r UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^s GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^t STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^u UNIVERSITY OF BOLOGNA   (Italy)

^v OSPEDALE NIGUARDA CA GRANDA   (Italy)

^w UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^x SCRIPPS CLINIC   (United States)

^y TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^z UNIVERSITY HOSPITAL BASEL   (Switzerland)

^aa SAPIENZA UNIVERSITY OF ROME   (Italy)

^ab NOVARTIS PHARMA AG   (Switzerland)

^ac OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; IMATINIB;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SKIN TOXICITY; SURVIVAL;

EID: 0037093092     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3530     Document Type: Article

References (49)

1. Sawyers, C.L., Chronic myeloid leukemia, (1999) New England Journal of Medicine, 340 (17), pp. 1330-1340
2. Faderl, S., Talpaz, M., Estrov, Z., Kantarjian, H.M., Chronic myelogenous leukemia: Biology and therapy, (1999) Annals of Internal Medicine, 131 (3), pp. 207-219
3. Karanas, A., Silver, R.T., Characteristics of the terminal phase of chronic granulocytic leukemia., (1968) Blood, 32 (3), pp. 445-459
4. Arlin, Z.A., Silver, R.T., Bennett, J.M., Blastic phase of chronic myeloid leukemia (blCML): A proposal for standardization of diagnostic and response criteria, (1990) Leukemia, 4 (11), pp. 755-757
5. Enright, H., McGlave, P., Chronic myelogenous leukemia, (2000) Hematology: Basic Principles and Practice. 3rd ed., pp. 1155-1171
6. Kantarjian, H.M., Dixon, D., Keating, M.J., Talpaz, M., Walters, R.S., McCredie, K.B., Freireich, E.J., Characteristics of accelerated disease in chronic myelogenous leukemia, (1988) Cancer, 61 (7), pp. 1441-1446
7. Speck, B., Bortin, MortimerM., Champlin, R., Goldman, JohnM., Herzig, RogerH., Mcglave, PhilipB., Messner, HansA., (...), Rimm, AlfredA., ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA, (1984) The Lancet, 323 (8378), pp. 665-668
8. Sokal, J.E., Baccarani, M., Russo, D., Tura, S., Staging and prognosis in chronic myelogenous leukemia, (1988) Seminars in Hematology, 25 (1), pp. 49-61
9. Derderian, P.M., Kantarjian, H.M., Talpaz, M., O'Brien, S., Cork, A., Estey, E., Pierce, S., (...), Keating, M., Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis, (1993) The American Journal of Medicine, 94 (1), pp. 69-74
10. Sacchi, S., Kantarjian, H.M., O'Brien, S., Cortes, J., Rios, M.B., Giles, F.J., Beran, M., (...), Talpaz, M., Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients, (1999) Cancer, 86 (12), pp. 2632-2641
11. Rowley, J.D., A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, (1973) Nature, 243 (5405), pp. 290-293
12. Nowell, P.C., Hungerford, D.A., A minute chromosome in human chronic granulocytic leukemia, (1960) Science, 132, pp. 1497-1501
13. Heisterkamp, N., Jenster, G., Ten Hoeve, J., Zovich, D., Pattengale, P.K., Groffen, J., Acute leukaemia in bcr/abl transgenic mice, (1990) Nature, 344 (6263), pp. 251-253
14. Daley, G.Q., Van Etten, R.A., Baltimore, D., Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome, (1990) Science, 247 (4944), pp. 824-830
15. Kelliher, M.A., McLaughlin, J., Witte, O.N., Rosenberg, N., Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL, (1990) Proceedings of the National Academy of Sciences of the United States of America, 87 (17), pp. 6649-6653
16. Elefanty, A.G., Hariharan, I.K., Cory, S., bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice, (1990) EMBO Journal, 9 (4), pp. 1069-1078
17. Iacoboni, S.J., Plunkett, W., Kantarjian, H.P., Estey, E., Keating, M.J., McCredie, K.B., Freireich, E.J., High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis, (1986) Journal of Clinical Oncology, 4 (7), pp. 1079-1088
18. Kantarjian, H.M., Talpaz, M., Kontoyiannis, D., Gutterman, J., Keating, M.J., Estey, E.H., O'Brien, S., (...), Deisseroth, A., Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor, (1992) Journal of Clinical Oncology, 10 (3), pp. 398-405
19. Kantarjian, H.M., O'Brien, S.M., Keating, M., Beran, M., Estey, E., Giralt, S., Kornblau, S., (...), Talpaz, M., Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia (Open Access), (1997) Leukemia, 11 (10), pp. 1617-1620
20. Dutcher, J.P., Eudey, L., Wiernik, P.H., Paietta, E., Bennett, J.M., Arlin, Z., Kellermeyer, R., (...), Cassileth, P.A., Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the eastern cooperative oncology group, (1992) Leukemia, 6 (8), pp. 770-775
21. Dutcher, J.P., Coletti, D., Paietta, E., Wiernik, P.H., A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia, (1997) Leukemia Research, 21 (5), pp. 375-380
22. Dann, E.J., Anastasi, J., Larson, R.A., High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase, (1998) Journal of Clinical Oncology, 16 (4), pp. 1498-1504
23. Montefusco, E., Petti, M.C., Alimena, G., Latagliata, R., Celesti, F., Capria, S., Amadori, S., (...), Mandelli, F., Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia (Open Access), (1997) Annals of Oncology, 8 (2), pp. 175-179
24. Schiffer, C.A., DeBellis, R., Kasdorf, H., Wiernik, P.H., Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213, (1982) Cancer Treatment Reports, 66 (2), pp. 267-271
25. Spencer, A., O'Brien, S.G., Goldman, J.M., OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA, (1995) British Journal of Haematology, 91 (1), pp. 2-7
26. Gratwohl, A., Hermans, J., Niederwieser, D., Frassoni, F., Arcese, W., Gahrton, G., Bandini, G., (...), Reiffers, J., Bone marrow transplantation for chronic myeloid leukemia: Long-term results, (1993) Bone Marrow Transplantation, 12 (5), pp. 509-516
27. McGlave, P.B., Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation, (1992) Leukemia, 6 (SUPPL. 4), pp. 115-117
28. Horowitz, M.M., Rowlings, P.A., Passweg, J.R., Allogeneic bone marrow transplantation for CML: A report from the International Bone Marrow Transplant Registry, (1996) Bone Marrow Transplantation, 17 (SUPPL. 3), pp. S5-S6
29. Brodsky, I., Biggs, J.C., Szer, J., Crilley, P., Atkinson, K., Downs, K., Dodds, A., (...), Copelan, E.A., Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): An update, (1993) Seminars in Oncology, 20 (4 SUPPL. 4), pp. 27-31
30. Brodsky, I., Biggs, J.C., Szer, J., Crilley, P., Atkinson, K., Downs, K., Dodds, A., (...), Copelan, E.A., Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): An update, (1993) Seminars in Oncology, 20 (4 SUPPL. 4), pp. 27-31
31. Deininger, M.W.N., Goldman, J.M., Lydon, N., Melo, J.V., The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells, (1997) Blood, 90 (9), pp. 3691-3698
32. Gambacorti-Passerini, C., Le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., (...), Lydon, N.B., Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis, (1997) Blood Cells, Molecules and Diseases, 23 (3), pp. 380-394
33. Druker, B.J., Lydon, N.B., Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia (Open Access), (2000) Journal of Clinical Investigation, 105 (1), pp. 3-7
34. Le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., (...), Gambacorti-Passerini, C., In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor (Open Access), (1999) Journal of the National Cancer Institute, 91 (2), pp. 163-168
35. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., (...), Sawyers, C.L., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, (2001) New England Journal of Medicine, 344 (14), pp. 1031-1037
36. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., (...), Talpaz, M., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, (2001) New England Journal of Medicine, 344 (14), pp. 1038-1042
37. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A., (...), Bloomfield, C.D., World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting - Airlie house, Virginia, November 1997, (1999) Journal of Clinical Oncology, 17 (12), pp. 3835-3849
38. Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C.A., (...), Sawyers, C.L., Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study, (2002) Blood, 99 (6), pp. 1928-1937
39. Coleman, M., Silver, R.T., Pajak, T.F., Cavalli, F., Rai, K.R., Kostinas, J.E., Glidewell, O., (...), Holland, J.F., Combination chemotherapy for terminal-phase chronic granulocytic leukemia: Cancer and leukemia group B studies, (1980) Blood, 55 (1), pp. 29-36
40. Le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., (...), Gambacorti-Passerini, C., Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification, (2000) Blood, 95 (5), pp. 1758-1766
41. Weisberg, E., Griffin, J.D., Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines, (2000) Blood, 95 (11), pp. 3498-350
42. Mahon, F.X., Deininger, M.W.N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J.M., Melo, J.V., Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance, (2000) Blood, 96 (3), pp. 1070-1079
43. Gambacorti-Passerini, C., Barni, R., Le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., (...), D'Incalci, M., Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL + leukemic cells to the Abl inhibitor STI571, (2000) Journal of the National Cancer Institute, 92 (20), pp. 1641-1650
44. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Nagesh Rao, P., Sawyers, C.L., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, (2001) Science, 293 (5531), pp. 876-880
45. Barthe, C., Cony-Makhoul, P., Melo, J.V., Mahon, J.R., Roots of clinical resistance to STI-571 cancer therapy., (2001) Science, 293 (5538), p. 2163
46. Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Lahaye, T., Berger, U., Cross, N.C., (...), D'Incalci, M., Roots of clinical resistance to STI-571 cancer therapy., (2001) Science, 293 (5538), p. 2163
47. Barthe, C., Cony-Makhoul, P., Melo, J.V., Mahon, J.R., Roots of clinical resistance to STI-571 cancer therapy., (2001) Science, 293 (5538), p. 2163
48. Topaly, J., Zeller, W.J., Fruehauf, S., Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells (Open Access), (2001) Leukemia, 15 (3), pp. 342-347
49. Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y., Furukawa, Y., In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents, (2001) Blood, 97 (7), pp. 1999-2007